Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow VTRS by emailGet an email when VTRS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VTRS, unsubscribe in one click. Privacy
📣 What VTRS Says Is Next
fourth quarter · “Completes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 Years PITTSBURGH – February 26, 2026 – Viatris Inc. (Nasdaq: VTRS) today announced robust financial results for the fourth quarter and full year 2025.”
Company press release, Feb 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full VTRS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VTRS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.